In a randomized double-blind, parallel- group trial, salmeterol plus fluticasone failed to reduce all-cause death in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) compared with each of the agents alone or placebo. The results of the Towards a Revolution in COPD Health (TORCH) trial were published in the New England Journal of Medicine (NEJM).
In a randomized double-blind, parallel- group trial, salmeterol plus fluticasone failed to reduce all-cause death in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) compared with each of the agents alone or placebo.
The results of the Towards a Revolution in COPD Health (TORCH) trial were published in the New England Journal of Medicine (NEJM).
The study included 6,112 current or former smokers from 42 countries. All patients were aged 40 to 80 years and had moderate, severe, or very severe COPD (ratio of prebronchodilator forced expiratory volume in 1 second [FEV1] to forced vital capacity [FVC] ≤0.70 and FEV1<60% of the predicted value). Patients were randomized to receive salmeterol 50 mcg plus fluticasone 500 mcg (n=1,533) twice daily, salmeterol 50 mcg alone twice daily (n=1,521), fluticasone 500 mcg alone twice daily (n=1,534), or placebo (n=1,524). The primary end point was the time to death from any cause during the 3 years of study follow-up. Secondary end points included the frequency of COPD exacerbations, changes in health status as determined by the St. George's Respiratory Questionnaire and spirometry, and the occurrence of adverse drug events.
In an accompanying editorial, Dr Klaus F. Rabe, a member of the Global Initiative for Obstructive Lung Disease (GOLD) and chair of the group's science committee, commented, "This finding confirms the position of combination therapy in current guidelines for the treatment of patients with COPD that recommend its use for those with severe COPD with frequent exacerbations but not for patients with milder disease or without frequent exacerbations."
Although therapy with salmeterol plus fluticasone did not demonstrate a reduction in mortality, the combination did demonstrate a reduction in the rate of COPD exacerbations from 1.13 to 0.85 annually (number needed to treat=4 patients to prevent 1 exacerbation in 1 year) and an improvement in patient health status; the combination also slowed the decline of scores on pulmonary function tests compared with placebo (P<.001 for all).
Fluticasone was associated with an increased risk of developing pneumonia when taken alone (18.3% probability) and in combination with salmeterol (19.6% probability) compared with placebo (12.3% probability) and salmeterol alone (13.3% probability).
Given the increased risk of pneumonia, Dr Rabe stated that there is an urgent need for further investigation into this combination therapy.
The National Heart Blood and Lung Institute (NHBLI) estimates that there may be as many as 16 million people in the United States diagnosed with COPD. It is the fourth-leading cause of death in the United States and is estimated to result in nearly three-quarters of a million hospitalizations annually. The total estimated cost of COPD in 2002 was $32.1 billion, including $18 billion in direct treatment costs and an additional $14.1 billion in lost productivity.
SOURCES
Calverley PMA, Anderson JA, Celli B, et al; for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
Rabe KF. Treating COPD-The TORCH trial, P values, and the dodo. N Engl J Med. 2007;356:851–854.
Global initiative for chronic obstructive lung disease. Executive summary: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http:// http://www.goldcopd.org/guidelineitem.asp?l1=2&l2=1&intid=996. Accessed March 22, 2007.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.